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high voluntary enrolment rate in the NRCMS a number of issues have been iden-
tified in the survey. Three key remedial actions in health financing, planning and
management to counteract the identified issues are proposed: 1) Enacting legisla-
tion and setting up a risk fund to ensure sustainability of the NRCMS; 2)The main
rights and responsibilities of related parties in the NRCMS should be clarified to
improve the incentive mechanism; and 3) Integrate disease prevention and the
reform of township hospitals.
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OBJECTIVES: To estimate the incidences of hospitalizations for statin-related ad-
verse events (AEs) and further evaluate the influence of the concomitant use of
fibrates or cytochrome P450 (CYP) 3A4 inhibitors on the risks of AEs in patients
initiating statin treatments. METHODS: A retrospective cohort study design was
employed with analyses from the Taiwan National Health Insurance Research Da-
tabase between January 1, 2000 and December 31, 2007. The study cohort com-
prised patients initially treated with statins, and was followed to observe the oc-
currence of hospitalizations for statin-associated AEs, including myopathy, renal
adverse events, hepatotoxic events and acute pancreatitis. Use of statins was fur-
ther categorized into three groups to examine the effect of concomitant use of the
interacting drugs: statin-fibrate combination, statin-CYP3A4 inhibitor combina-
tion, and statin monotherapy. Poisson regressions were used to estimate the indi-
vidual incidences and incidence rate ratios (IRRs) of hospitalization events for the
combined therapies versus statin monotherapy. RESULTS: A total of 53,594 statin
initiators were identified as the study cohort, with atorvastatin and lovastatin
being observed as the most commonly prescribed statins. The proportion of statin
initiators concomitantly treated with fibrates and CYP3A4 inhibitors was 7.1% and
14.3%, respectively. Overall, the highest incidence occurred in renal adverse events
(36.8/10,000 person-years), followed by hepatotoxic events, acute pancreatitis, and
myopathy. A similar ranking order of the incidences was observed across the three
groups. Compared to statin monotherapy, combination therapy of statins with the
interacting medications increased the risks of overall AEs (statin-fibrate combina-
tion: adjusted IRR, 2.01; 95% CI, 1.21-3.32; statin-CYP3A4 inhibitor combination:
adjusted IRR, 2.29; 95% CI, 1.73-3.02). CONCLUSIONS: Renal toxicity is found to be
the most frequently occurring AE during statin treatments. Concomitant use of
statins with fibrates or CYP3A4 inhibitors increases the risks of statin-associated
AEs, which warrants caution for close monitoring of adverse symptoms when st-
atins are used concurrently with the potential interacting drugs.
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OBJECTIVES: To evaluate the association between use of antipsychotics and risk of
stroke in patients with cardiovascular diseases (CVDs).METHODS: This was a ret-
rospective nested case-control study analyzing data from the National Health In-
surance Research Database in Taiwan. A cohort of all patients with CVDs initiating
an antipsychotic was identified during January 1, 1998 and December 31, 2006.
Cases were defined as those with hospitalizations for stroke (ICD9-CM codes 430-
438, A-code A29), and the date of stroke admission was referred as the index date.
Using the incidence density sampling approach, each case was matched to ten
randomly-selected controls on age ( 5 years), sex and cohort entry date ( 365
days). Controlswere assigned the same index date as their corresponding case. Use
of antipsychotics was measured during a six-month period before the index date
and categorized into typical or atypical class. Conditional logistic regressions were
used to estimate odds ratios (ORs).RESULTS:The study cohort comprised 6773 CVD
patients, fromwhich 533 cases and 5057matched controls were identified. Any use
of atypical antipsychotics was associated with an increased risk of stroke when
compared with typical antipsychotics (adjusted OR, 1.46; 95 % CI, 1.01-2.10). Addi-
tionally, the comparative risk was increased to a greater extent as atypical antip-
sychotics were prescribed within 90 days before the index date (adjusted OR, 1.94;
95% CI, 1.34-2.83). Further stratified analyses indicated that any use of atypical
antipsychotics was associated with a 1.55-fold increased risk of stroke in the el-
derly population. CONCLUSIONS: Use of atypical antipsychotics is associated with
an increased risk of stroke relative to typical antipsychotics among patients with
CVDs, and the risk is further increased as atypical antipsychotics are prescribed
more currently. Clinicians should be aware of the stroke risk while prescribing
antipsychotics for patients with underlying CVDs, especially in the elderly.
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OBJECTIVES: To determine the outcome and the prognostic factors among severe
sepsis and septic shock (SS&SK) survivors one year after hospital discharge.
METHODS: This was a retrospective and cross-sectional study of patients (18
years) admitted 24 hours between April 2007 and March 2010 for the first time to
themedical-surgical and trauma intensive care unit (ICU) of a tertiary hospital and
discharged from the hospital alive. For patients withmore than one ICU admission
within the same hospitalization, only first ICU admission was counted. Data ob-
tained from an electronic ICU database, hospital information system and medical
records. Additionally, We conducted telephonic interviews to evaluate vital status
and performance at one year of hospital discharge using KARNOFSKY PERFOR-
MANCE STATUS SCALE. Patients who had cardiac arrest were excluded from the
study. RESULTS: The overall mortality rate was 35%. One-third (31%) of who were
still survive at one year post hospital discharge, suffer from significant (P0.05)
impairment of performance status. SS&SK survivors who had CHF had 3.4 times
higher risk to die as compared to who did not had CHF. Pre-sepsis performance
status and CHF were the independent prognostic factors for poor hospital out-
comes on long term post hospital discharge in SS&SK survivors. CONCLUSIONS:
About one third of patients die by one year, another one-third suffer from signifi-
cant impairment of performance status. Pre-sepsis performance status and CHF
were the independent prognostic factors in SS&SK survivors. This data highlights
the need for different strategies for caring of SS&SK survivors.
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OBJECTIVES: Thrombolytic therapy is widely accepted as a standard treatment for
patients diagnosed with ST-Elevated Acute Coronary Syndrome (ACS). Enoxaparin
has been the most commonly used medicine but its increased risk of bleeding is a
major concern. Fondaparinux has been available with a potentially better safety
profile, but there still no direct head to head study comparing these two agents.
This study aims to determine the comparative efficacy and safety of enoxaparin
and fondaparinux for treating ST-Elevated ACS using a network meta-analysis.
METHODS:We undertook a systematic review to identify studies from computer-
ized databases including Pubmed, Cochrane and Clinical Trial.gov. Inclusion crite-
ria are 1) RCT in STEMI patients receiving fibrinolytic agent, and 2) Using Enoxa-
parin or Fondaparinux. Efficacy outcome was death or myocardial re-infarction at
30 days, while safety outcome wasmajor bleeding event during in hospital or at 30
days. All studies were extracted independently by 2 reviewers. Heterogeneity was
tested using Q-statistics and I2 test. Indirect comparison based on a networkmeta-
analysis under a random-effects model was used to synthesize the comparison
between these 2 products. RESULTS: Seven studies were included in this study (6
compared Enoxaparin and UFH and 1 Compared Fondaparinux and UFH). The re-
sult of network meta-analysis indicated similar efficacy between fondaparinux
and enoxaparin (OR  1.12 (CI: 0.76-1.65), with the lower risk of major bleeding in
the fondaparinux group (OR  0.40 (CI: 0.17-0.96). There was no heterogeneity
revealed from Q-statistics and I2. CONCLUSIONS: Our study indicated that among
patients with STEACS receiving fibrinolytic agent, fondaparinux has similar effi-
cacy on death/myocardial infarction but statistically significant lower bleeding
event compared with enoxaparin. Fondaparinux seems to have favorable risk/
benefit profile compared with Enoxaparin when used in STEMI patients receiving
fibrinolytic agents.
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OBJECTIVES: Statins are the first-line drug therapy in the treatment of hypercho-
lesterolemia. The beneficial clinicalimpact of statins on the cardiovascular system
resultsnot only from their lipid-lowering action but also from their pleiotropic
effects. Recently, it has been suggested thatstatins can reduce blood pressure;
however the available data are still ambiguousand often conflicting. Therefore we
performed the meta-analysis to investigate the potential hypotensive action of
statins in patients with or without hypertension. METHODS: Data from Scopus,
PubMed,Web of Science, and the Cochrane Central Register of Controlled Trials for
years 1966 to October 2011 were searched for studies that investigated the effect of
statins on blood pressure either in normotensive or hypertensive subjects.
RESULTS: Finally themeta-analysis included 18 trials - 5628 subjects (4692 normo-
tensive, 936 hypertensive) randomized to receive either statins or placebo.The
standardized effect size of mean differences of systolic (DSBP) and diastolic blood
pressure (DDBP) in normotensive patients for ten included trials for statins therapy
was 0.006 (95%CI: -0.052-0.063; p0.84) and -0.03 (95%CI: -0.09-0.03; p0.3), respec-
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tively. For hypertensive patients treated with statins (8 included trials) the stan-
dardized effect size of DSBP andDDBPwas 0.07 (95%CI: -0.07-0.21; p0.33) and -0.12
(95%CI: -0.36-0.11; p0.31), respectively. CONCLUSIONS: Despite previous sugges-
tions, statin therapy in normotensive or hypertensive patients does not lead to
reductions in systolic and diastolic blood pressure. Despite these results, however,
the routine use of statins, especially in patients with hypertension should be al-
ways considered due to the essential reduction of cardiovascular events.
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OBJECTIVES: The first coronary drug-eluting stent gained its market approval in
Europe 2002. Many different drug-eluting stents came to the market worldwide
since then. In Taiwan, National Health Insurance has partially reimbursed drug-
eluting stents since 2006. The number of claimed usage increased from 521 (year
2006) up to 14,311 (year 2010), and total claimed reimburse went up from NTD 15
million to 300 million. The impact to the NHI has been increasing. The aim of this
study is to summarize the results of Taiwan drug-eluting stents studies for future
researches.METHODS:We systematically searched three bibliographic databases:
EMBASE, PubMed and Taiwan National Central Library for studies utilizing Taiwan
local data. In order to collect as many local studies as we can, no restrictions were
applied onpublication year, study type, disease, patients, intervention, comparator
and outcomes. RESULTS: Among the 73 studies we identified in EMBASE and
PubMed, only one randomized control trial was found. The authors tried to evalu-
ate the preventive outcome of phosphorycholine-coated dexamethasone stent by
observing restenosis rate. We then expanded our analysis scopes to controlled
trials, and additional 26 studieswere identified and 3 studiesmatched our research
question. Their topics were about “1 year follow-up after PCI with Titan versus
TAXUS stents”, “gender differences in patients undergoing coronary stenting” and
“the effects of starting statin therapy before PCI with drug-eluting stents”. On the
other part of our research at Taiwan National Central Library, there was no paper
matched our including criteria. Most of the papers included there were coronary
stents design related articles. CONCLUSIONS: Based on systematically research
results, we only found one randomized control trial fully used Taiwan local data.
Lack of comparative effectiveness on local stents usage could pose a problemwhen
considering evidence-based decision making.
PCV7
IMPLEMENTING AND EVALUATING PHARMACIST-MANAGED WARFARIN
SERVICE IN INPATIENT AND OUTPATIENT SETTING IN TAIWAN
Wang YP1, Tseng JH2, Huang SY3
1Taipei Medical University – Shuang Ho Hospital, New Taipei City, New Taipei City, Taiwan,
2Taipei Medical University – Shuang Ho Hospital, New Taipei City, New Taipei City, Taiwan,
3Taipei Medical University – Shuang Ho Hospital, New Taipei City, New Taipei city, Taiwan
OBJECTIVES: To identify approaches and to evaluate efficacy of implementing an
warfarin service program involving pharmacists. METHODS: The pharmacy de-
partment worked with the medical staff to establish a warfarin service, including
guidelines approval. Pharmacist-managed warfarin service was provided in neu-
rology ward or for patients who were referred from physicians, and others re-
mained standard care of anticoagulants. Data was collected for 3 months after the
service implementation (March toMay, 2011). Demographic and clinical character-
istics as well as laboratory and clinical data were retrieved from institutional elec-
tronic databases and compared between the pharmacist-managed and standard-
care cohort. Comparisons between study groups were conducted using a 2 or
Fisher’s Exact test for categorical variables and a two sample t-test or Wilcoxon
rank sum test for continuous variables. RESULTS: INR below the therapeutic range
were observed less frequently (53.3% vs. 61.1%, P0.35) and better control for INR
within rangewere reportedmore (28.6% vs. 26.9%, P0.80) in pharmacist-managed
arm, when compared to standard-care arm. There were also fewer number of
patients never reaching the INR goal during the whole study period (35.7% vs.
46.1%, P0.52). None of major bleeding event occurred, however, one thrombotic
event was observed in each arm. By intervention of pharmacists, possible adverse
event and medication errors were also blocked. For example, one patient dis-
charged while INR over 5 without any physicians’ or nurses’ awareness was ac-
tively informed by pharmacist, then contacted to be cautious with possible bleed-
ing risks andmanagement. CONCLUSIONS: Pharmacist-managed warfarin service
had a positive impact on anticoagulationmanagement. This study provides further
evidence to support the of role pharmacists in anticoagulant therapy. We plan to
expend the warfarin service experience to the overall institution in the future.
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OBJECTIVES: To develop evaluation criteria comparing efficacy and safety of anti-
hypertensive drugs and to perform comparative analysis based on the developed
criteria on the pre- existing antihypertensive drugs on reimbursement list in Korea.
METHODS: A total of 1226 items with 131 ingredients were categorized into 5
classes: Diuretics, -blocker, Calcium channel blocker, Angiotensin—converting-
enzyme inhibitors, Angiotensin-Receptor-blocker. Proxy and final outcomes eval-
uating efficacy of antihypertensive drugswere determined based on previous stud-
ies and opinion of experts. For proxy outcomes, Systolic Blood Pressure and
Diastolic Blood Pressure were used while all-cause mortality, cardiovascular mor-
tality, and cardiovascular morbidity were used as final outcomes. Proper criteria
evaluating safety are impossible to choose because symptoms and frequency of
adverse event varies depending on classes. Systematic review literatures in Korea
and other countries were searched using databases such as Pubmed, Cochrane,
Embase, Center for Review&Dissemination, KMBase, and KoreaMed. In addition, 6
assessment reports from overseas health technology institutions and opinions of
clinical experts were referenced. Finally, 7 literatures using proxy outcomes and 8
literatures using final outcomes were reviewed in-depth after through screening.
Additional statistical analysis was not performed. RESULTS: On in-depth exami-
nation, there was no profound evidence depicting difference in proxy and final
outcomes among classes and among ingredients in the same class. Results of 6
overseas technical reports aforementioned were the same as the ones of SR liter-
atures. Opinions of clinical experts confirmed the findings of in-depth examination
in proxy outcomes adding that efficacy in final outcomes can be different depend-
ing on the co-morbidity status. CONCLUSIONS: It was not proven that a particular
class or ingredient is superior to others. Therefore, it is expected that if reimburse-
ment list is reorganized based on this result, improvement of public health and
saving of health insurance finance is feasible without depriving the prescription
rights of clinicians.
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OBJECTIVES: Stevioside is a major constituent of the plant Stevia rebaudiana Ber-
toni (SRB). Its beneficial effect on human blood pressure has been demonstrated in
many studies, with no significant adverse effects being reported. This meta-anal-
ysis was aimed to evaluate the efficacy and safety of stevioside against placebo in
blood pressure control in hypertensive patients. METHODS: A systematic search
for relevant studieswas performed of the PubMed, ScienceDirect, Cochrane Library
and Wiley Online Library databases from their respective inception until Fabruary
2012. The bibliography of the retrieved studies was also examined. Stevia rebaudi-
ana Bertoni, stevioside, hypertension and randomized controlled trial were used as
searching keywords. The studies were included if they: 1. were randomized con-
trolled trials (RCTs) comparing stevioside from SRB with placebo in hypertensive
patients; 2. reported on systolic blood pressure (SBP) and diastolic blood pressure
(DBP); and 3. were published in English. Data were pooled using the inverse vari-
ance-weighted method and statistical analyses were performed using the Review
Manager (RevMan) version 5.1.4. RESULTS: Three RCTs involving altogether 280 pa-
tients were included in the analysis. Stevioside was found to be effective in reducing
SBP, with no significant effect on DBP, compared to placebo. The pooled mean differ-
ences in SBP and DBP were -10.43 mmHg (95% CI: -12.15 to -8.72 mmHg, p0.01) and
-6.67mmHg (95%CI: -13.23 to -0.10mmHg, p0.05), respectively. No significant differ-
ence in adverse events was reported between the two groups (OR: 1.32, 95% CI: 0.61 to
2.86). CONCLUSIONS: Our findings suggest the efficacy of stevioside in reducing
SBP but not DBP in hypertensive patients. Additionally, stevioside was shown to
produce no significant adverse events in this group of patients.
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OBJECTIVES: Cardiovascular diseases are the most frequent cause of morbidity
andmortality inmany countries. That explains whymedications for the treatment
of cardiovascular diseases are group of drugs with largest consumption, and ACE
inhibitors take a large part in the consumption. The aim of this study was to
analyze the consumption of prescribed ACE inhibitors, in Serbia during year 2009.
METHODS: The data about the use of ACE inhibitors were obtained from the Re-
public Fund of Health Insurance of the Serbia (RFZO). RESULTS: Total consumption
of ACE inhibitors in year 2009 was 176,29 DDD and total financial outlay was
59.772.897,11€. Largest use of plain ACE inhibitors was for enalapril (78,32 DDD),
fosinopril (20,09 DDD), ramipril (19,11 DDD) and cilazapril (14,19 DDD). The volume
of their consumption is not in accordance with the funding spent for these prod-
ucts. Enalapril, which has the highest percentage of consumption in this group of
44,43%, has 28,73% of total allocated funds, while the consumption for fosinopril
amounts to 11,40%while 18,69%of fundswithin the group is allocated for this drug. In
Norway and Sweden, country with developed pharmacotherapeutic practice, highest
usage of plain ACE inhibitors was for ramipril and enalapril. In these countries, other
more expensive products are significantly less likely to be used. If the consumption
structure of ACE inhibitors in Serbia in 2009 was as in Norway, but with the same
volume of consumption RFZO would save about 9.500.000,00€ only for plain ACE
inhibitors.CONCLUSIONS:Viewed from the perspective of the RFZO, large financial
resources would be saved if the structure of the utilized ACE inhibitors in Serbia
was more similar to the country with developed pharmacotherapeutic practice.
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